Antisense & RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular Disorder, Genetic Disorder), By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030
Antisense & RNAi Therapeutics Market Growth & Trends
The global antisense & RNAi therapeutics market size is expected to reach USD 14.66 billion by 2030, registering a CAGR of 18.12% from 2024 to 2030, according to a new report by Grand View Research, Inc. Developments in biological vectors & nanotechnology and increased financial help for clinical investigations, including the launch of novel drug molecules, are critical in product development and are driving market expansion.
Multinational healthcare organizations raise awareness and assist in the development of novel remedies for a variety of ailments. Private institutes and companies participating in conducting trials through supporting research institutes are predicted to considerably fuel sector expansion. For instance, in March 2022, Biogen Inc. and Ionis Pharmaceuticals, Inc. announced outcomes from the Phase 1 study of an investigational antisense oligonucleotide for treating people with amyotrophic lateral sclerosis (ALS). Such increasing clinical trials through industry participants is anticipated to propel the market growth by rising the product launches based on antisense and RNAi therapies.
Antisense and RNAi therapies can be used to treat various disorders that impact the cell growth cycle and target nucleic acids. The ability of miRNA to regenerate gene expression and regulate protein production, consequently impacting industrial advancement, is receiving much attention. According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome. Such advancements in the industry are expected to propel the demand for RNAi and antisense therapeutics for treating numerous diseases over the forecast period.
Antisense & RNAi Therapeutics Market Report Highlights
- Antisense RNA technology accounted for the largest revenue share in 2023 in the technology segment due to its wide applications in diseases like neurodegenerative and genetic conditions.
- The RNA interference segment is anticipated to witness the fastest growth in technology. This technology is further segmented into siRNA & miRNA. Due to miRNA's important role in sustaining cell identity, it's being employed to understand cancer spread better.
- Based on application, the genetic disease segment's dominance can be attributed to key players' increasing focus on developing novel genetic disease treatments.
- North America accounted for the largest revenue share in the global antisense and RNAi therapeutics market. The region's dominance can be attributed to the presence of several players in the region and their efforts to strengthen their position in the industry.
- Europe is anticipated to register the fastest growth over the forecast period from 2024 to 2030, owing to key companies like Secarna operating and expanding in the region.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Route of Administration
- 1.2.3. Application
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline.
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Route of Administration outlook
- 2.2.3. Application outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Antisense & RNAi Therapeutics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Presence of strong pipeline product portfolio
- 3.2.1.2. Introduction of technological advancements in drug delivery
- 3.2.1.3. Implementation of favorable government initiatives & external funding for R&D exercises
- 3.2.1.4. Rising collaborations between pharmaceutical companies
- 3.2.2. Market restraint analysis
- 3.2.2.1. Expensive and tedious research programs
- 3.2.2.2. Delivery of RNAi therapeutics and off-target effects
- 3.3. Antisense & RNAi Therapeutics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.2. PESTEL Analysis
- Chapter 4. Antisense & RNAi Therapeutics Market: Technology Estimates & Trend Analysis
- 4.1. Technology Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Antisense & RNAi Therapeutics Market by Technology Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. RNA Interference
- 4.4.1.1. RNA Interference Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Antisense RNA
- 4.4.2.1. Antisense RNA Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 5. Antisense & RNAi Therapeutics Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Antisense & RNAi Therapeutics Market by Application Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Ocular
- 5.4.1.1. Ocular Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.2. Cardio metabolic & Renal Disorders
- 5.4.2.1. Cardio metabolic & Renal Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.3. Respiratory Disorders
- 5.4.3.1. Respiratory Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.4. Cancer
- 5.4.4.1. Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.5. Neurodegenerative Disorders
- 5.4.5.1. Neurodegenerative Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.6. Genetic Disorders
- 5.4.6.1. Genetic Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.7. Infectious Diseases
- 5.4.7.1. Infectious Diseases Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.8. Skin Diseases
- 5.4.8.1. Skin Diseases Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.9. Others
- 5.4.9.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)
- Chapter 6. Antisense & RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis
- 6.1. Route of Administration Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Antisense & RNAi Therapeutics Market, by Route of Administration Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Intravenous Injections
- 6.4.1.1. Intravenous Injections Market estimates and forecasts, 2018 to 2030 (USD million)
- 6.4.2. Intrathecal Injections
- 6.4.2.1. Intrathecal Injections Market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4.3. Subcutaneous Injections
- 6.4.3.1. Subcutaneous Injections Market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4.4. Others
- 6.4.4.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)
- Chapter 7. Antisense & RNAi Therapeutics Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2023 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.5. North America
- 7.5.1. U.S.
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Target disease prevalence
- 7.5.1.3. Regulatory framework
- 7.5.1.4. Competitive scenario
- 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.2. Canada
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Target disease prevalence
- 7.5.2.3. Regulatory framework
- 7.5.2.4. Competitive scenario
- 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6. Europe
- 7.6.1. UK
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Target disease prevalence
- 7.6.1.3. Regulatory framework
- 7.6.1.4. Competitive scenario
- 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.2. Germany
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Target disease prevalence
- 7.6.2.3. Regulatory framework
- 7.6.2.4. Competitive scenario
- 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.3. France
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Target disease prevalence
- 7.6.3.3. Regulatory framework
- 7.6.3.4. Competitive scenario
- 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.4. Italy
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Target disease prevalence
- 7.6.4.3. Regulatory framework
- 7.6.4.4. Competitive scenario
- 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.5. Spain
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Target disease prevalence
- 7.6.5.3. Regulatory framework
- 7.6.5.4. Competitive scenario
- 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.6. Norway
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Target disease prevalence
- 7.6.6.3. Regulatory framework
- 7.6.6.4. Competitive scenario
- 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.7. Sweden
- 7.6.7.1. Key country dynamics
- 7.6.7.2. Target disease prevalence
- 7.6.7.3. Regulatory framework
- 7.6.7.4. Competitive scenario
- 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.8. Denmark
- 7.6.8.1. Key country dynamics
- 7.6.8.2. Target disease prevalence
- 7.6.8.3. Regulatory framework
- 7.6.8.4. Competitive scenario
- 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7. Asia Pacific
- 7.7.1. Japan
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Target disease prevalence
- 7.7.1.3. Regulatory framework
- 7.7.1.4. Competitive scenario
- 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.2. China
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Target disease prevalence
- 7.7.2.3. Regulatory framework
- 7.7.2.4. Competitive scenario
- 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.3. India
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Target disease prevalence
- 7.7.3.3. Regulatory framework
- 7.7.3.4. Competitive scenario
- 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.4. Australia
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Target disease prevalence
- 7.7.4.3. Regulatory framework
- 7.7.4.4. Competitive scenario
- 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.5. South Korea
- 7.7.5.1. Key country dynamics
- 7.7.5.2. Target disease prevalence
- 7.7.5.3. Regulatory framework
- 7.7.5.4. Competitive scenario
- 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.6. Thailand
- 7.7.6.1. Key country dynamics
- 7.7.6.2. Target disease prevalence
- 7.7.6.3. Regulatory framework
- 7.7.6.4. Competitive scenario
- 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.8. Latin America
- 7.8.1. Brazil
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Target disease prevalence
- 7.8.1.3. Regulatory framework
- 7.8.1.4. Competitive scenario
- 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.8.2. Mexico
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Target disease prevalence
- 7.8.2.3. Regulatory framework
- 7.8.2.4. Competitive scenario
- 7.8.2.5. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.8.3. Argentina
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Target disease prevalence
- 7.8.3.3. Regulatory framework
- 7.8.3.4. Competitive scenario
- 7.8.3.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.9. MEA
- 7.9.1. South Africa
- 7.9.1.1. Key country dynamics
- 7.9.1.2. Target disease prevalence
- 7.9.1.3. Regulatory framework
- 7.9.1.4. Competitive scenario
- 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.9.2. Saudi Arabia
- 7.9.2.1. Key country dynamics
- 7.9.2.2. Target disease prevalence
- 7.9.2.3. Regulatory framework
- 7.9.2.4. Competitive scenario
- 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.9.3. UAE
- 7.9.3.1. Key country dynamics
- 7.9.3.2. Target disease prevalence
- 7.9.3.3. Regulatory framework
- 7.9.3.4. Competitive scenario
- 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.9.4. Kuwait
- 7.9.4.1. Key country dynamics
- 7.9.4.2. Target disease prevalence
- 7.9.4.3. Regulatory framework
- 7.9.4.4. Competitive scenario
- 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2023
- 8.3.4. Olix Pharmaceuticals
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. GSK plc
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Sanofi
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Alnylam Pharmaceuticals, Inc.
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Ionis Pharmaceuticals, Inc.
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Benitec Biopharma Inc
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Silence Therapeutics
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Arbutus Biopharma
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. Bio-Path Holdings Inc
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Product benchmarking
- 8.3.12.4. Strategic initiatives
- 8.3.13. Antisense Therapeutics Limited.
- 8.3.13.1. Company overview
- 8.3.13.2. Financial performance
- 8.3.13.3. Product benchmarking
- 8.3.13.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook